Tenaya Therapeutics: Column Group reports 21.6% stake
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Tenaya Therapeutics, Inc. (TNYA) ownership amendment reports that The Column Group Opportunity III, LP and four related reporting persons each report beneficial ownership of the same 49,313,559 common shares, or 21.6% of the class. The shares are held of record by the partnership, with shared voting and dispositive power reported through its general-partner structure and its managing members, Tim Kutzkey and Peter Svennilson.
The amendment updates the reported ownership percentage to reflect dilution caused by the issuer’s sales of additional shares since the original Schedule 13D. Tenaya had 227,928,240 shares outstanding as of October 29, 2026. The reported amount excludes warrants for 35,714,284 shares held by the partnership, which are not exercisable within 60 days due to the Beneficial Ownership Limitations.
Key Figures
Key Terms
beneficial ownership technical
Beneficial Ownership Limitations technical
pecuniary interest technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why did the reporting persons update their TNYA ownership filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.